Logo for Candel Therapeutics Inc

Candel Therapeutics Investor Relations Material

Latest events

Logo for Candel Therapeutics Inc

Study Result

Candel Therapeutics
Logo for Candel Therapeutics

Study Result

11 Dec, 2024
Logo for Candel Therapeutics

Q3 2024

14 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Candel Therapeutics Inc

Access all reports
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer treatment. The company’s approach involves using genetically modified viruses to induce immunogenic cell death in cancer cells, which unmask tumor antigens within an activated microenvironment. This process triggers a systemic and durable immune response against tumors, acting as an in situ vaccination. Candel’s therapies are designed to potentially improve survival rates and maintain the quality of life for patients across various stages of cancer. The company is headquartered in Needham, Massachusetts, and its shares are listed on NASDAQ.